In a noteworthy update for investors, Doximity, Inc. (DOCS) has been assigned a “Hold” rating by Gene Mannheimer of Freedom Capital Markets on September 8, 2026. This rating, which comes with a price target of $27, aligns closely with the current trading price of $26.35, suggesting limited upside potential but possibly steady performance for cautious investors.
Recent Price Action
The stock of Doximity, Inc. has exhibited pronounced volatility in recent trading sessions, reflecting broader market uncertainties. As of the latest closing price of $26.35, DOCS has experienced a noteworthy decline of 5.52%, down $1.46 over the trading day. For the past 52 weeks, the stock has fluctuated between a low of $6.67 and a high of $67.19, indicating significant swings that have contributed to a heightened beta of 1.248. The trading volume for the day reached approximately 1,042,827 shares, against an average volume of 4,752,986, suggesting that while there is interest, it remains below the recent norm. This imbalance in volume could hint at a cautious investor sentiment weighing on the stock’s dynamics.
[chart type=’price’ value=’DOCS’]
Short- and Long-Term Performance
Doximity’s performance over the recent weeks illustrates broader challenges faced by the company. Over the past 30 days, the stock has declined by 5.97%. This trend deepens over a three-month span where DOCS has recorded a staggering quarterly performance decline of 39.17%. Year-to-date, Doximity shares are down 22.76%, showcasing the challenges confronting the firm in an evolving healthcare technology landscape. Additionally, the stock has shown a weekly volatility of 4.35% and a monthly volatility of 3.55%, further emphasizing the potential for rapid changes in sentiment and pricing, likely driven by market news and investor reactions.
[chart type=’performance’ value=’DOCS’]
Earnings and Financials
The latest earnings report, dated August 6, 2026, produced mixed results for Doximity. The company reported an earnings per share (EPS) of $0.29, which fell short of the estimated EPS of $0.303, resulting in a surprise factor of -4.29%. This outcome contrasts starkly with the previous quarter when the EPS of $0.10 far underperformed the estimate of $0.28, achieving a significant negative surprise of 64.29%. The consecutive misses may signal underlying operational challenges and could prompt further scrutiny from investors on the company’s strategic direction and execution.
[chart type=’income-bar-chart’ value=’DOCS’]
Analyst and Consensus View
The sentiment surrounding Doximity as expressed by analysts reflects a cautious outlook. Freedom Capital Markets’ Mannheimer issued a “Hold” rating based on three total ratings: two hold ratings and one sell. The average price target currently rests at approximately $24.67, positioning it below the short-term target of $27 but above the low projection of $20. This generally conservative consensus indicates that analysts are neither overly bullish nor bearish, recognizing potential but also identifying risks tied to the company’s recent performance.
[chart type=’analyst-ratings’ value=’DOCS’]
Stock Grading or Fundamental View
Doximity finds itself holding an overall Stocks Telegraph Grade of 56, a mixed grade that provides an impression of the company’s health and investment profile. This score reflects moderate financial stability yet underscores the necessity for improvement in certain operational facets. Key attention will likely be placed on the company’s ability to innovate and adjust its business model amidst changing market dynamics, particularly those adoption trends seen in the telehealth and healthcare software sectors.
[chart type=’st-cards’ value=’DOCS’]
Conclusion
Doximity, Inc. serves as a compelling consideration for investors seeking moderate exposure in the healthcare technology space. With its recent “Hold” rating, this stock may attract investors with a defensive stance looking for stability despite ongoing market fluctuations. However, those considering an investment should be aware of the risks, particularly in light of recent earnings performance and the overall trend of declining stock returns. While the fundamentals support a case for cautious investment, close monitoring of operational efficiencies and market reactions will be essential for those looking to gain or maintain a position in DOCS.